Identification of Master Regulators Driving Disease Progression, Relapse, and Drug Resistance in Lung Adenocarcinoma

Identification of Master Regulators Driving Disease Progression, Relapse, and Drug Resistance in Lung Adenocarcinoma

Backgrounds: Lung cancer is the leading cause of cancer related death worldwide. Current treatment strategies primarily involve surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy, determined by TNM stages, histologic types, and genetic profiles. Plenty of studies have been tryi...

Full description

Bibliographic Details
Main Authors:	Qiong Xu, Qiongfang Cha, Hui Qin, Bin Liu, Xueling Wu, Jiantao Shi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-01-01
Series:	Frontiers in Bioinformatics
Subjects:	lung adenocarcinoma relapse TKI resistance immunotherapy master regulator
Online Access:	https://www.frontiersin.org/articles/10.3389/fbinf.2022.813960/full

Similar Items

Systemic Inflammation Response Index (SIRI) Independently Predicts Survival in Advanced Lung Adenocarcinoma Patients Treated with First-Generation EGFR-TKIs
by: Jiang S, et al.
Published: (2021-02-01)

Almonertinib-induced interstitial lung disease in a lung adenocarcinoma patient complicated with interstitial lung abnormality
by: Qian Zhou, et al.
Published: (2023-03-01)

Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs
by: Fei Zhou, et al.
Published: (2018-10-01)

Rechallenge with EGFR-TKI after failure of immunotherapy is considered an effective treatment for advanced lung adenocarcinoma patients with EGFR exon 19 deletion: a case report
by: Shubin Chen, et al.
Published: (2023-06-01)

Genomic profile and immune microenvironment in patients with relapsed stage IA lung adenocarcinoma
by: Lu Yang, et al.
Published: (2021-01-01)

Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
by: Da Hyun Kang, et al.
Published: (2020-06-01)

Outcomes of salvage lung resections in advanced EGFR‐mutant lung adenocarcinomas under EGFR TKIs
by: Ying‐Yuan Chen, et al.
Published: (2021-10-01)

NFIX as a Master Regulator for Lung Cancer Progression
by: Nor I. A. Rahman, et al.
Published: (2017-08-01)

Management of medically inoperable and tyrosine kinase inhibitor-naïve early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: a retrospective multi-institutional analysis
by: Yuemei Sun, et al.
Published: (2020-07-01)

Systematical identifications of prognostic meaningful lung adenocarcinoma subtypes and the underlying mutational and expressional characters
by: Zhenyang Lv, et al.
Published: (2020-01-01)

Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor
by: Byoung Soo Kwon, et al.
Published: (2020-02-01)

Malignant mesothelioma without asbestos exposure diagnosed during EGFR-TKI treatment of lung adenocarcinoma: A case report
by: Xiaomin Niu, et al.
Published: (2021-01-01)

DCLK1 Drives EGFR-TKI-Acquired Resistance in Lung Adenocarcinoma by Remodeling the Epithelial–Mesenchymal Transition Status
by: Rui Yan, et al.
Published: (2023-05-01)

STE029 Overcomes EGFR-TKI Resistance in Human Lung Adenocarcinoma
by: Lin HUANG, et al.
Published: (2022-11-01)

Sinus metastasis of lung adenocarcinoma: a case report
by: Mingyuan Xu, et al.
Published: (2024-01-01)

Comparing the Efficacy of Two Generations of EGFR-TKIs: An Integrated Drug–Disease Mechanistic Model Approach in EGFR-Mutated Lung Adenocarcinoma
by: Hippolyte Darré, et al.
Published: (2024-03-01)

Lung adenocarcinoma presents with diffuse bone metastasis
by: Jinye Mi, et al.
Published: (2021-10-01)

Can CT Radiomics Detect Acquired T790M Mutation and Predict Prognosis in Advanced Lung Adenocarcinoma With Progression After First- or Second-Generation EGFR TKIs?
by: Xiaohuang Yang, et al.
Published: (2022-07-01)

Nuclear Pore Glycoprotein 62 Genetic Variant rs9523 is Associated with Clinical Outcomes of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Adenocarcinoma Patients
by: Park JE, et al.
Published: (2021-10-01)

Lactate regulators contribute to tumor microenvironment and predict prognosis in lung adenocarcinoma
by: Shipeng Shang, et al.
Published: (2022-11-01)

Regulation of Ferroptosis in Lung Adenocarcinoma
by: Xiangyun Wei, et al.
Published: (2023-09-01)

EGFR Thr790Leu as a Potential Resistance Mechanism to First-Generation EGFR Tyrosine Kinase Inhibitor May Respond to Osimertinib in Patients With Lung Adenocarcinoma
by: Chan Xiang, PhD, et al.
Published: (2021-07-01)

LncRNA BC promotes lung adenocarcinoma progression by modulating IMPAD1 alternative splicing
by: Qi Wen Chen, et al.
Published: (2023-01-01)

A Comprehensive Analysis of the Effects of Key Mitophagy Genes on the Progression and Prognosis of Lung Adenocarcinoma
by: Dongjun Dai, et al.
Published: (2022-12-01)

Detailed Analysis and Radiomic Prediction of First Progression Sites of First-Line Targeted Therapy for EGFR-Mutant Lung Adenocarcinoma Patients With Systemic Metastasis
by: Xiaoyang Li, et al.
Published: (2021-10-01)

Comparison of the Incidence Rate of Radiation Pneumonitis Observed in Patients with Advanced Lung Adenocarcinoma Treated with Simultaneous Thoracic Radiotherapy and 1G/2G/3G EGFR-TKIs
by: Mu F, et al.
Published: (2023-04-01)

Utility of Multiple Increased Lung Cancer Tumor Markers in Treatment of Patients with Advanced Lung Adenocarcinoma
by: Yan PENG, et al.
Published: (2017-10-01)

Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases
by: Haoran Qi, et al.
Published: (2024-03-01)

Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease
by: Daniele Marinelli, et al.
Published: (2022-10-01)

Cosuppression of NF-κB and AICDA Overcomes Acquired EGFR-TKI Resistance in Non-Small Cell Lung Cancer
by: Min-Kyung Yeo, et al.
Published: (2022-06-01)

Impact of Different Treatment Regimens and Timeframes in the Plasmatic Metabolic Profiling of Patients with Lung Adenocarcinoma
by: Daniela Madama, et al.
Published: (2023-11-01)

Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status
by: Tetsuya Isaka, et al.
Published: (2022-09-01)

Functions and clinical significance of KLRG1 in the development of lung adenocarcinoma and immunotherapy
by: Xiaodong Yang, et al.
Published: (2021-06-01)

Construction and validation of a T cell proliferation regulator-related signature for predicting prognosis and immunotherapy response in lung adenocarcinoma
by: Wuguang Chang, et al.
Published: (2023-04-01)

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
by: Hao Sun, et al.
Published: (2020-10-01)

Prognostic Factors in Patients with Advanced Lung Adenocarcinoma Treated with Icotinib
by: ZHANG Hongbin, et al.
Published: (2022-11-01)

Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators
by: Yong Qin, et al.
Published: (2017-06-01)

Case report: Osimertinib administration during pregnancy in a woman with advanced EGFR-mutant non-small cell lung cancer
by: Pamela Soberanis Pina, et al.
Published: (2023-03-01)

“Cheerios in the lung” as first metastases from endometrial endometrioid adenocarcinoma with adequate response to immunotherapy
by: Chiara De Nardo, et al.
Published: (2023-09-01)

Integrative Analysis of the Expression of SIGLEC Family Members in Lung Adenocarcinoma via Data Mining
by: Haiyan Zhang, et al.
Published: (2021-03-01)